Stem cell treatment trials of spinal cord injuries in animals

Farid, Mariam; Abouelela, Yara S.; Rizk, Hamdy

doi:10.1016/j.autneu.2021.102932

Cited by 14 publications

(15 citation statements)

References 101 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Animal models have proven to be extremely useful in understanding the mechanism of the disease and the possible therapeutic interventions [9][10][11]. Cats, like other animals, suffer from a variety of neurological disorders, including the consequences of traumas, inflammations, congenital malformations, and infections.…”

Section: Introductionmentioning

confidence: 99%

A novel cell-free intrathecal approach with PRP for the treatment of spinal cord multiple sclerosis in cats

et al. 2022

View full text Add to dashboard Cite

Background Multiple sclerosis (MS) is a progressive autoimmune demyelinating disease of the central nervous system. To date, there is no effective therapy for it. Our study aimed to determine the potential role of platelet-rich plasma (PRP) in the treatment of MS in cats. Methods The current study was conducted on 15 adult Persian cats that were divided into three groups: control negative, control positive (ethidium bromide (EB)-treated group), and PRP co-treated group (EB-treated group intrathecally injected with PRP on day 14 post-spinal cord injury). PRP was obtained by centrifuging blood on anticoagulant citrate dextrose and activating it with red and green laser diodes. The Basso–Beattie–Bresnahan (BBB) scores were used to assess the motor function recovery on days 1, 3, 7, 14, 20, and 28 following 14 days from EB injection. Moreover, magnetic resonance imaging (MRI) analysis, histopathological investigations, transmission electron microscopy (TEM) studies, and immunohistochemical analysis were conducted, and the gene expressions of nerve growth factors (NGFs), brain-derived neurotrophic factors (BDNF), and stromal cell-derived factors (SDF) were evaluated. Results Our results indicated that PRP had a significant ameliorative effect on the motor function of the hindlimbs as early as day 20 and so on. MRI revealed that the size and intensity of the lesion were significantly reduced in the PRP co-treated group. The histopathological and TEM investigations demonstrated that the PRP co-treated group had a significant improvement in the structure and organization of the white matter, as well as a high remyelination capacity. Furthermore, a significant increase in myelin basic protein and Olig2 immunoreactivity as well as a reduction in Bax and glial fibrillar acidic protein immune markers was observed. NGFs were found to be upregulated by gene expression. Conclusion As a result, we concluded that the intrathecal injection of PRP was an effective, safe, and promising method for the treatment of MS.

show abstract

Section: Introductionmentioning

confidence: 99%

A novel cell-free intrathecal approach with PRP for the treatment of spinal cord multiple sclerosis in cats

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In the last decades, stem cell therapy has emerged as a very promising solution in the field of SCI. After a plethora of encouraging treatment trials using different types of stem cells in animals of different species [ 5 ], clinical trials involving humans with SCI became a reality in the middle of the first decade of this century. This review addresses the pathophysiology of SCI, the possible mechanisms of action of different stem cells in spinal cord repair, and it presents the basic characteristics and results of the related clinical trials published in the PubMed online library in the last five years.…”

Section: Introductionmentioning

confidence: 99%

Stem Cell Therapy for Spinal Cord Injury: A Review of Recent Clinical Trials

Damianakis¹,

Benetos²,

Evangelopoulos³

et al. 2022

Cureus

View full text Add to dashboard Cite

Spinal cord injury (SCI) remains an incurable, life-changing neurological condition, causing permanent loss of motor and sensory function in millions of people worldwide and affecting them in every aspect of their personal and social life. In the last two decades, after its success in various fields of medicine, stem cell therapy has been investigated in the research field as a potential treatment for SCI. This review focuses on the pathophysiology of SCI, the characteristics of the different stem cell therapies used for its treatment, and the results of these therapies in recently published clinical trials.

show abstract

“…66,67 In several preclinical studies, the therapeutic potential of NSCs derived from ESCs or iPSCs has been demonstrated in animal models of SCI. 8,26,29,31 To date, human clinical data using ESCs or iPSCs for SCI treatment are scarce. Only two clinical trials (one in each ESCs and iPSCs) are ongoing right now.…”

Section: A C C E P T E D a R T I C L Ementioning

confidence: 99%

“…Information about the potential mechanism of action of stem cells in the disease indication, the timing of intervention with respect to disease course, and the mode of delivery to the site of action must be investigated in preclinical models. Many preclinical studies using NSCs in animal models of SCI have been reported in the literature, 8,26,29,31 and the therapeutic potential, safety, and several technical aspects of NSCs transplantation have been tested under various conditions. The characteristics of experimental studies using NSCs are summarized in Table 1.…”

Section: A C C E P T E D a R T I C L E Preclinical Study Of Neural St...mentioning

confidence: 99%

Advances in Neural Stem Cell Therapy for Spinal Cord Injury: Safety, Efficacy, and Future Perspectives

et al. 2022

View full text Add to dashboard Cite

Spinal cord injury (SCI) is a devastating central nervous system (CNS) injury that leads to severe disabilities in motor and sensory functions, causing significant deterioration in patients' quality of life.Owing to the complexity of SCI pathophysiology, there has been no effective treatment for reversing neural tissue damage and recovering neurological functions. Several novel therapies targeting different stages of pathophysiological mechanisms of SCI have been developed. Among these, treatments using stem cells have great potential for the regeneration of damaged neural tissues. In this review, we have summarized recent preclinical and clinical studies focusing on neural stem cells (NSCs). NSCs are multipotent cells with specific differentiation capabilities for neural lineage. Several preclinical studies have demonstrated the regenerative effects of transplanted NSCs in SCI animal models through both paracrine effects and direct neuronal differentiation, restoring synaptic connectivity and neural networks. Based on the positive results of several preclinical studies, phase I and II clinical trials using NSCs have been performed. Despite several hurdles and issues that need to be addressed in the clinical use of NSCs in patients with SCI, gradual progress in the technical development and therapeutic efficacy of NSCs treatments has enhanced the prospects for cell-based treatments in SCI.

show abstract

Stem cell treatment trials of spinal cord injuries in animals

Cited by 14 publications

References 101 publications

A novel cell-free intrathecal approach with PRP for the treatment of spinal cord multiple sclerosis in cats

A novel cell-free intrathecal approach with PRP for the treatment of spinal cord multiple sclerosis in cats

Stem Cell Therapy for Spinal Cord Injury: A Review of Recent Clinical Trials

Advances in Neural Stem Cell Therapy for Spinal Cord Injury: Safety, Efficacy, and Future Perspectives

Contact Info

Product

Resources

About